INTRODUCTION
• Malignant ascites (MA) is a common complication of peritoneal carcinomatosis associated with a poor quality of life (QoL) • MA is mostly related to epithelial tumors expressing the epithelial cell-adhesion molecule (EpCAM) including epithelial ovarian (EOC), endometrial (EC), and breast carcinoma (BC) • The trifunctional monoclonal antibody catumaxomab (CATU; anti-EpCAM x anti-CD3) was approved by the European Medicines Agency (EMA) Figure 2E ) Median: 56 days; range: 8-1130 days • Overall survival (Figure 2A) Median 79.5 days; range : 9-1130 days • Predictors for both puncture-free and overall survival were (see Table 2 
